NASDAQ:ALGS Aligos Therapeutics Q1 2024 Earnings Report $9.16 +0.12 (+1.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$9.03 -0.13 (-1.41%) As of 07/18/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Aligos Therapeutics EPS ResultsActual EPS-$5.50Consensus EPS -$4.75Beat/MissMissed by -$0.75One Year Ago EPSN/AAligos Therapeutics Revenue ResultsActual Revenue$0.99 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAligos Therapeutics Announcement DetailsQuarterQ1 2024Date5/7/2024TimeN/AConference Call DateTuesday, May 7, 2024Conference Call Time4:00PM ETUpcoming EarningsAligos Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aligos Therapeutics Earnings HeadlinesAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | globenewswire.comAligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)June 18, 2025 | globenewswire.comMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.July 20 at 2:00 AM | Crypto Swap Profits (Ad)Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | globenewswire.comAligos Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comAligos Stock Price HistoryMay 26, 2025 | investing.comSee More Aligos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email. Email Address About Aligos TherapeuticsAligos Therapeutics (NASDAQ:ALGS) (NASDAQ: ALGS) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapeutics for the treatment of viral diseases and liver disorders. Headquartered in South San Francisco, California, Aligos is advancing a pipeline of both small molecule and nucleic acid-based programs designed to achieve functional cures or meaningful clinical improvements in patients with chronic hepatitis B virus (HBV) infection and nonalcoholic steatohepatitis (NASH). The company’s research engine integrates cutting-edge chemistry, immunology and RNA biology to create targeted therapies that address multiple stages of the viral lifecycle and modulate host immune responses. Lead programs include orally administered inhibitors that target HBV replication and novel RNA interference (RNAi) assets aimed at silencing viral and fibrotic pathways in the liver. Preclinical candidates are also being evaluated for their potential to enhance antiviral immunity and reverse liver fibrosis in NASH patients. Founded in 2014, Aligos has drawn on venture capital support and strategic partnerships to build its scientific platform and advance assets through clinical development. The company went public in 2020, listing its shares on the NASDAQ under the ticker ALGS. Since inception, Aligos has maintained a commitment to rigorous translational research, leveraging in-house manufacturing capabilities and external collaborations to optimize its drug candidates for safety, potency and delivery. Aligos conducts its clinical trials across the United States, Europe and Asia, engaging leading medical centers and patient communities to generate robust data in diverse populations. The company is led by a team of seasoned biotechnology executives and scientific leaders with extensive experience in virology, hepatology and drug development. Together, they aim to deliver transformational therapies that address significant unmet needs in chronic liver disease and viral infection.Written by Jeffrey Neal JohnsonView Aligos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
